Articles related to BREAST CANCER

The 100-μg dose of the ERBB2 ICD plasmid-based vaccine was associated with the generation of ERBB2-specific type 1 T cells in the majority of patients with ERBB2-expressing breast cancer in this phase 1 nonrandomized clinical trial, and it is currently being assessed in randomized phase 2 trials.

Cancer Therapy Advisor provides a variety of resources, including regimens used to supplement the most recent treatment strategies. Examine all regimens here.

With just a few exceptions (p.I157T, p.S428F, and p.T476M), CHEK2 PVs were linked to comparable cancer phenotypes regardless of the variation type. Although CHEK2 PVs were linked to breast, kidney, and thyroid malignancies, they were not linked to colorectal cancer. The prevalent p.I157T, p.S428F, and p.T476M alleles have a weaker connection with breast cancer compared to other CHEK2 PVs and were not related with non-breast malignancies. These findings might help with genetic counseling and care for those with CHEK2 PVs.

A 29-year-old woman bought a genetic test that includes BRCA analysis. She comes to you with the results and asks for guidance. The results are negative for BRCA1 and BRCA2, but she has a positive family history for breast cancer. What do you advise?

This trial included 33 patients with clinical node-positive locally advanced breast cancer who underwent NET and breast surgery. MRI exams were performed before the first treatment regimen, at least two months after the first treatment cycle but prior to crossing-over, and immediately before surgery. MRI did not demonstrate sufficient diagnostic performance to avoid surgical axillary staging in the authors’ analysis.

The prospective, open-label, single-arm, phase 2 TUXEDO-1 trial enrolled patients with HER2-positive breast cancer and newly diagnosed untreated brain metastases or brain metastases progressing after previous local therapy. Patients received trastuzumab deruxtecan intravenously at the standard dose of 5.4 mg per kg bodyweight once every 3 weeks. Fifteen patients received at least one dose of study drug. Two patients (13.3%) had a complete intracranial response, nine (60%) had a partial intracranial response and three (20%) had stable disease as the best intracranial response. There were no new safety signals.